--- title: "CUTIA's self-developed local anesthetic cream has been approved for market launch by the mainland drug regulatory authority" type: "News" locale: "en" url: "https://longbridge.com/en/news/285456969.md" description: "CUTIA-B announced that its self-developed local anesthetic cream \"CU-30101\" has been approved for market launch by the National Medical Products Administration of China. This product combines lidocaine and bupivacaine to provide rapid and long-lasting anesthetic effects with good safety. The launch is based on the results of Phase III clinical trials completed in China. CU-30101 is the company's first approved product in the field of epidermal anesthesia, which will help expand sales channels and strengthen its presence in the dermatological treatment market" datetime: "2026-05-06T23:56:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285456969.md) - [en](https://longbridge.com/en/news/285456969.md) - [zh-HK](https://longbridge.com/zh-HK/news/285456969.md) --- # CUTIA's self-developed local anesthetic cream has been approved for market launch by the mainland drug regulatory authority According to a report from Economic Information Daily on the 6th, CUTIA-B (02487) announced that its self-developed topical lidocaine and bupivacaine cream "CU-30101" has been approved for market launch by the National Medical Products Administration of China, intended for epidermal anesthesia procedures. The company stated that CU-30101 is a topical cream combining lidocaine and bupivacaine, which, due to the different pharmacokinetic properties of the two components, can provide rapid and lasting anesthetic effects. Lidocaine has a faster diffusion rate, while bupivacaine is a long-acting local anesthetic with higher lipophilicity, allowing it to concentrate in the epidermal stratum corneum. Additionally, the topical cream formulation helps reduce systemic absorption, thus ensuring good safety. The approval for market launch is primarily based on the results of a Phase III clinical trial conducted in China. The company noted that the analgesic efficacy of CU-30101 is comparable to that of the reference product Pliaglis, with overall good safety, and local tolerance performance similar to Pliaglis, with no new safety signals identified. CU-30101 is the group's first product approved for market launch in the field of epidermal anesthesia, and it is the third approved product following CU-10201 (topical 4% minocycline foam) and CU-40102 (topical finasteride spray). The board believes that the approval of CU-30101 will help the group further expand sales channels and facilitate the commercialization of subsequent products, further strengthening the group's commercial layout in the dermatology treatment and care market. (eh) ### Related Stocks - [02487.HK](https://longbridge.com/en/quote/02487.HK.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) ## Related News & Research - [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md) - [Cutia Therapeutics AGM resolutions passed in shareholder vote](https://longbridge.com/en/news/290935117.md) - [China closing in but US still leads in biotech innovation, survey finds](https://longbridge.com/en/news/290431706.md) - [Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio](https://longbridge.com/en/news/285457203.md)